---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-25-000090"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:24:25.122251+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Agios responds to analyst report on PYRUKYND safety data; Saudi Arabia approves PYRUKYND for thalassemia

## Summary
- Analyst report on Aug 4, 2025 references four FAERS cases; Agios says benefit-risk profile unchanged.
- Three cases reported to Agios: two for PK deficiency patients on commercial PYRUKYND, one expanded access for sickle cell.
- Fourth case reported directly to FDA; Agios evaluating via pharmacovigilance processes.
- Saudi FDA approved PYRUKYND for adult patients with alpha- or beta-thalassemia (both non-transfusion and transfusion dependent).

## SEC filing metadata
- accession: 0001439222-25-000090
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000090/0001439222-25-000090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000090/agio-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-25-000090
- JSON: https://secwatch.observer/filing/0001439222-25-000090.json
- Plain text: https://secwatch.observer/filing/0001439222-25-000090.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.